Drug Profile
BMS 981164
Alternative Names: BMS981164; IL-31 mAB - Bristol-Myers Squibb; IL-31 monoclonal antibody - Bristol-Myers SquibbLatest Information Update: 19 Apr 2016
Price :
$50
*
At a glance
- Originator ZymoGenetics
- Developer Bristol-Myers Squibb; ZymoGenetics
- Class Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Interleukin 31 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Atopic dermatitis; Inflammation
Most Recent Events
- 01 Apr 2015 Bristol-Myers Squibb completes a phase I trial in Atopic dermatitis in United Kingdom (NCT01614756)
- 16 Apr 2014 Bristol-Myers Squibb initiates enrolment in a phase I trial for Atopic dermatitis in United kingdom (UKCRN13421)
- 01 Jul 2012 Phase-I clinical trials in Atopic dermatitis in United Kingdom (SC, IV) (NCT01614756)